 
RAZIEL THERAPEUTICS  LTD . 
 
INVESTIGATIONAL NEW DRUG PROTOCOL  
 
RZL -012 
PROTOCOL NUMBER RZL -012-SMF -SWMTG -P2US -001 
VERSION 1.2 
15 NOVEMBER 2022 
 
AN OPEN LABEL PHASE 2 STUDY TO EVALUATE THE EFFECTS OF A LOCAL 
ANESTHETIC, ANTI -INFLAMMATORY MEDICATIONS AND COMPRESSION 
GARMENTS ON RZL -012-INDUCED ADVERSE EVENTS  
SPONSOR:  
Raziel Therapeutics, Ltd. 
10 Plaut Str.  
Rehovot, Israel 76 10000  
 
CONFIDENTIAL   
This document is a confidential communication of Raziel Therapeutics, Ltd. Acceptance of this 
document constitutes agreement by the recipient that no unpublished information contained herein 
will be published or disclosed without prior written approval, except for disclosure to the 
appropriate Institutional Review Board and/or Regulatory Authority under the condition that 
confidentiality is maintained.  
 
Version 1.0 :  03 AUGUST  2022  
Version 1.1: 19 September 2022  
Version 1.2: 15 November 2022  
        
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 2 of 44 CONFIDENTIAL  
 KEY CONTACTS FOR THE STUDY  
SPONSOR’S  
REPRESENTATIVES:   
Sponsor Contact  Richard E. Lowenthal, M Sc, MBA  
Program Manager  
Pacific -Link Research Inc.  
Cell: +1 -858-335-1300  
Tel: +1-858-227-3008  
E-mail: richard @pacificlinkconsulting.com  
 
Study Director  Racheli Gueta , PhD  
Raziel Therapeutics  
Director, Clinical Development  
Cell:  + 972-50-7837597  
E-mail: racheli@raziel -therapy .com  
 
Study Medical Monitor  Patricia Walker, MD   
E-mail: dr.patricia.walker@gmail.com  
 
Serious Adverse Event Reporting  
 
 
 
 
 
  MedicalMonitorSupport@rhoworld.com  
Jamie_Chang@rhoworld.com  
SAE Hotline: 888 -746-7231  
SAE Fax Line: 888 -746-3293  
SAE Email: 
rho_productsafety@rhoworld.com  
 
 
 
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 3 of 44 CONFIDENTIAL  
 TABLE OF CONTENTS  
LIST OF TABLES  ................................ ................................ ................................ ..........................  6 
LIST OF FIGURES  ................................ ................................ ................................ ........................  6 
LIST OF APPENDICES  ................................ ................................ ................................ .................  6 
STATEMENT OF COMPLIANCE  ................................ ................................ ................................  9 
INVESTIGATOR STATEMENT  ................................ ................................ ................................  10 
1.0 PROTOCOL SUMMARY  ................................ ................................ ................................ . 11 
1.1 Protocol Synopsis ................................ ................................ ................................ ...............  11 
1.2 Schedule of Activities  ................................ ................................ ................................ ........  17 
2.0 INTRODUCTION  ................................ ................................ ................................ .............  18 
1.1. Study Rationale  ................................ ................................ ................................ ..................  18 
1.2. Scientific Background  ................................ ................................ ................................ ........  18 
1.2.1.  Non-Clinical Studies  ................................ ................................ ................................ ........  18 
1.2.2.  Clinical Studies  ................................ ................................ ................................ ................  19 
1.3. Risk-Benefit Assessment  ................................ ................................ ................................ ... 20 
1.3.1.  Identified RZL -012 Risks  ................................ ................................ ................................  20 
1.3.2.  Benefits  ................................ ................................ ................................ ............................  21 
3.0 STUDY OBJECTIVES AND ENDPOINTS  ................................ ................................ ..... 22 
3.1 Study Objectives  ................................ ................................ ................................ ................  22 
3.1.1  Primary Objective  ................................ ................................ ................................ ..............  22 
3.1.2  Secondary Objectives ................................ ................................ ................................ .........  22 
3.2 Study Endpoints  ................................ ................................ ................................ .................  22 
3.2.1  Primary Endpoint  ................................ ................................ ................................ ...............  22 
3.2.2  Exploratory Endpoints  ................................ ................................ ................................ ....... 22 
4.0 STUDY DESIGN ................................ ................................ ................................ ...............  23 
4.1 Overall Design  ................................ ................................ ................................ ...................  23 
4.2 Rationale for Study Design  ................................ ................................ ................................  23 
4.3 Rationale for Study Dose  ................................ ................................ ................................ ... 24 
5.0 STUDY POPULATION  ................................ ................................ ................................ .... 24 
5.2 Exclusion Criteria  ................................ ................................ ................................ ..............  25 
6.0 STUDY INTERVENTION  ................................ ................................ ................................  26 
6.1 Study Intervention Administration  ................................ ................................ ....................  26 
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 4 of 44 CONFIDENTIAL  
 6.1.1  Study Intervention Description  ................................ ................................ ..........................  26 
6.2 Preparation/Handling/Storage/Accountability  ................................ ................................ ... 28 
6.3 Study Intervention Compliance  ................................ ................................ .........................  29 
6.4 Prior and Concomitant Medications  ................................ ................................ ..................  29 
7.0 STUDY INTERVENTION DISCONTINUATION  ................................ ..........................  29 
8.0 STUDY ASSESSMENTS AND PROCEDURES  ................................ .............................  30 
8.1 Medical History  ................................ ................................ ................................ .................  30 
8.2 Height  ................................ ................................ ................................ ................................ . 30 
8.3 Weight  ................................ ................................ ................................ ................................  30 
8.4 Pregnancy Tests  ................................ ................................ ................................ .................  30 
8.5 Complete Physical Examination  ................................ ................................ ........................  30 
8.6 Clinician -Chin Assessment Tool (C -CAT)  ................................ ................................ ........  31 
8.7 Subject – Self-Chin Assessment Tool (S -CAT)  ................................ ................................  31 
8.8 Magnetic Resonance Imaging (MRI)  ................................ ................................ .................  32 
8.9 2-D Standardized Photography  ................................ ................................ ..........................  33 
8.10  Subject’s Satisfaction Questionnaire  ................................ ................................ .................  33 
8.11  Biochemistry  ................................ ................................ ................................ ......................  35 
8.12  Vital Signs  ................................ ................................ ................................ ..........................  35 
8.13  ECG ................................ ................................ ................................ ................................ .... 35 
8.14  Adverse Events and Serious Adverse Events  ................................ ................................ .... 35 
8.14.1  Collection of Adverse Events Data  ................................ ................................ ....................  35 
8.14.2  Serious Adverse Events  ................................ ................................ ................................ ..... 37 
8.14.3  Reporting Requirements for Serious Adverse Events  ................................ .......................  37 
8.14.4  Reporting pregnancy  ................................ ................................ ................................ ..........  38 
8.14.5  Recording of Serious Adverse Events  ................................ ................................ ...............  38 
9.0 STATISTICAL CONSIDERATIONS ................................ ................................ ...............  39 
9.1 Sample Size Determination ................................ ................................ ................................  39 
9.2 Analysis Data Sets  ................................ ................................ ................................ .............  39 
9.3 Endpoints Analyses  ................................ ................................ ................................ ............  39 
9.4 Safety  ................................ ................................ ................................ ................................ . 39 
10.0  DATA COLLECTION, STUDY MONITORING, AND DATA DISCLOSURE  ............  40 
10.1  Data Collection and Reporting ................................ ................................ ...........................  40 
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 5 of 44 CONFIDENTIAL  
 10.2  Study Monitoring  ................................ ................................ ................................ ...............  40 
10.3  Audit and Inspection  ................................ ................................ ................................ ..........  40 
10.4  Deviation from Clinical Trial Protocol  ................................ ................................ ..............  40 
10.5  Retention of Records ................................ ................................ ................................ ..........  41 
10.6  Data Disclosure and Subject Confidentiality  ................................ ................................ ..... 41 
11.0  PROTECTION OF HUMAN SUBJECTS  ................................ ................................ ........  42 
11.1  Basic Principles  ................................ ................................ ................................ ..................  42 
11.2  Institutional Review Board/Ethics Committee  ................................ ................................ .. 42 
11.3  Informed Consent ................................ ................................ ................................ ...............  42 
11.4  Subject Health Injury and Insurance  ................................ ................................ ..................  43 
11.5  Completion of the Study  ................................ ................................ ................................ .... 43 
 
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 6 of 44 CONFIDENTIAL  
 LIST OF TABLES  
Table 1  Estimated Cumulative Exposure from Clinical Studies  ................................ .............  19 
Table 2  Clinician Chin Assessment Tool (C -CAT)  ................................ ................................ . 31 
Table 3  Self Chin Assessment Tool (S -CAT)  ................................ ................................ .........  32 
Table 4  Severity Assessment of Adverse Events  ................................ ................................ .... 36 
Table 5  Contact Information for SAE Reporting  ................................ ................................ .... 38 
 
LIST OF FIGURES  
Figure 1  Submental Injection Pattern ................................ ................................ ........................  28 
 
LIST OF APPENDICES  
Appendix A:   Photographic Standards of the Face Area  ................................ .......................  44 
 
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 7 of 44 CONFIDENTIAL  
 LIST OF ABBREVIATIONS  
ABBREVIATION  DEFINITION  
ADR  Adverse drug reaction  
AE Adverse event  
ALP  Alkaline phosphatase  
ALT  Alanine transaminase  
AST  Aspartate aminotransferase  
BMI  Body mass index  
BUN  Blood urea nitrogen  
CBC  Complete blood count  
C-CAT  Clinician Chin Assessment Tool  
cGMP  Current Good Manufacturing Practices  
CI Confidence interval  
cm Centimeter  
CNS  Central nervous system  
CRF  Case report form  
CV Coefficient of variable  
DD Dercum’s disease  
ECG  Electrocardiograms  
FDA  Food and Drug Administration  
GLP  Good Laboratory Practice  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH-GCP  International Conference on Harmonization  Good Clinical Practice  
IND Investigational New Drug  
INR International normalized ratio  
IRB/EC  Institutional Review Board/Ethics Committee  
kg Kilogram  
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 8 of 44 CONFIDENTIAL  
 ABBREVIATION  DEFINITION  
LDH  Lactate dehydrogenase  
MedDRA  Medical Dictionary for Regulatory Activities  
mg milligram  
mL milliliter  
MOA  Mechanism of action  
MRI  Magnetic resonance imaging  
N Number of subjects  
NSAID  Non-steroidal anti -inflammatory drugs  
PT Prothrombin time  
PTT Partial thromboplastin time  
RBC  Red blood count  
SAE  Serious adverse event  
S-CAT  Subject Chin Assessment Tool  
SMF  Submental fat  
SOP Standard operating procedure  
TEAE  Treatment emergent adverse event(s)  
US/USA  United States of America  
WBC  White blood cell  
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 9 of 44 CONFIDENTIAL  
 STATEMENT OF COMPLIANCE  
This clinical trial will be conducted in compliance with the protocol, International Conference on 
Harmonization Good Clinical Practice E6 and the applicable regulatory requirements.  
  
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 10 of 44 CONFIDENTIAL  
 INVESTIGATOR STATEMENT  
I have read and understand the protocol and agree to implement the study in accordance with the 
procedures set forth in the protocol and in accordance with the Sponsor's guidelines, all 
applicable government regulations, and the International Conference on  Harmonization  Good 
Clinical Practice Guidelines E6 (ICH -GCP).  
I will maintain accurate source documents from which data are transcribed onto case report 
forms and accurate drug accountability records that show the receipt and disposition of all study 
drugs.  
I will provide adequate protocol training to my associates, colleagues, and employees assisting in 
the conduct of the study.  
I will obtain Institutional Review Board/Ethics Committee (IRB/EC) approval of the protocol and 
Informed Consent Form  (ICF)  prior to enrollment of subjects in the study. I understand that any 
modifications to the protocol made during the course of the study must first be approved by the 
IRB/EC prior to implementation except when such modification is made to remove an immediate  
hazard to the subject.  
I will ensure that a fully executed IRB -approved Informed Consent Form is obtained from each 
subject prior to initiation of any study procedures.  
I will report (within 24 hours) any serious adverse event, regardless of relationship to study drug, 
or pregnancy that occurs during the course of the study, in accordance with the procedures 
described in Section 8.14.3  of the protocol. I will notify the Sponsor if I become aware that a 
partner of a study subject becomes pregnant while the subject was receiving this study drug.  
I will submit all protocol inclusion/exclusion violations to the Medical Monitor for approval prior 
to enrollment of the subject in the study.  
I will allow the Sponsor, Raziel Therapeutics Ltd.  (Raziel) and its agents, as well as the United 
States (U.S.) Food and Drug Administration (FDA) and other regulatory agencies to inspect study 
facilities and pertinent records at reasonable times and in a reasonable manner, ensuring subject 
confidentiality. If I am  notified that this study is to be inspected by a regulatory agency, I will 
notify the Sponsor as soon as possible thereafter (no later than one  week).  
This protocol contains information that is proprietary to Raziel .  The information contained herein 
is provided for the purpose of conducting a clinical trial for Raziel . 
The contents of this protocol may be disclosed to study personnel under your supervision and to 
your IRB/EC. The contents of this protocol may not be disclosed to any other parties (unless such 
disclosure is required by government regulations or laws) with out the prior written approval of 
Raziel.  
 
__________________ ____     _______________________ _______       ________________  
Investigator’s Name                Investigator’s Signature    Date  
 
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 11 of 44 CONFIDENTIAL  
 1.0 PROTOCOL SUMMARY  
1.1 Protocol Synopsis  
Study Title  An Open Label Phase 2 Study to Evaluate the Effects of a Local Anesthetic, Anti -
inflammatory Medications and Compression Garments on RZL -012-Induced Adverse 
Events (RZL -012-SMF -SWMTG -P2US -001) 
Phase  Phase 2  
Study Drug  RZL -012 
Study Objectives 
and Endpoints  Primary Objective:  
• To compare the benefits of lidocaine, methylprednisolone ,  Celecoxib + cetirizine or 
compression dressings on RZL -012-induced adverse events  
Secondary Objectives:  
• To test the safety and tolerability profile of combining lidocaine, methylprednisolone , 
Celecoxib +  cetirizine  or compression garment with RZL -012 
Primary Endpoint:  Safety and tolerability profile of combining lidocaine , methylprednisolone  
,  Celecoxib +cetirizine or a compression garment with RZL -012 
Exploratory  Endpoints:  
• Proportion of subjects   who have at least a 1 -grade improvement in the C -CAT on Day 
84 versus baseline in subjects receiving RZL -012 alone or in combination with other 
medications .  
• Proportion of subjects   who have at least a 1 -grade improvement in the S -CAT on Day 
84 versus baseline in subjects receiving RZL -012 alone or in combination with other 
medications . 
• Proportion of subjects   who have at least a 1 -grade improvement in both C -CAT and S -
CAT on Day 84 versus baseline in subjects receiving RZL -012 alone or in combination 
with other medications . 
• Proportion of subjects   who have at least a 2 -grade improvement in both C -CAT and S -
CAT on Day 84 versus baseline in subjects receiving RZL -012 alone or in combination 
with other medications . 
• Changes in SMF volume measured by MRI scans on Day 84 versus baseline in subjects 
receiving RZL -012 alone or in combination with other medications . 
• Satisfaction in subjects receiving RZL -012 alone or in combination with other 
medications . 
Study Design  This is a Phase 2, open -label, 2 -stage, adaptive -design study in which subjects will be 
randomized into one of 5 treatment groups comprised of RZL -012 with or without 
additional study treatments:  
1. RZL -012 alone  
2. RZL -012 and 1% lidocaine with 1:100,000 epinephrin e (on Day 1) – 5ml lidocaine will 
be injected 10 minutes before RZL -012 treatment  
3. RZL -012 and oral methylprednisolone  dose pack  (8 mg (2 tablets) on Day 1  before 
treatment  followed by 16 mg after treatment (as per Instructions for Use) ). From Day 2, a  
daily tapering off by 4 mg until Day 6  will be administered per Rx Instructions for use . 
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 12 of 44 CONFIDENTIAL  
 4. RZL -012 and Celecoxib and cetirizine  (200 mg Celecoxib BID and 10 mg cetirizine  BID 
on Days 1, 2, 3, 4, 5 and 6)  
5. RZL -012 + s ling/pressure garment (until Day 6)  
In the first stage of the study, 5 subjects will be randomized into each of the treatment 
groups. Study outcomes will be assessed up to one week thereafter to determine the need to 
modify additional study treatments. Subsequently up to 10 additional subjec ts will be 
randomized into each of the treatment groups for the second  stage  of the study.   
For each subject, the study will consist of a screening period, baseline period in which 
subjects will receive a single treatment session of RZL -012 and a follow -up period.  RZL -
012 will be administered during a single treatment session via multiple inject ions into the 
submental area under the chin. Subjects will thereafter be monitored for safety and efficacy 
for at least 84 days.  
Each subject will be treated with the same dose of RZL -012 :  
• RZL -012 (concentration of injected solution 50 mg/mL RZL -012) of 7.5 mg/0.15 
mL/injection point that results in a total dose/volume of 240±30mg mg /4.8±0.6 
mL RZL -012, 
Each subject will receive additional study treatments in accordance with the treatment 
group to which the subject is randomized.  
Screening Period:   
Subjects will undergo screening within 28 days prior to being treated with RZL -012. 
During the screening period subjects will be assessed for study eligibility by evaluation of 
subjects’ SMF using S -CAT , C -CAT, biochemistry blood tests,  MRI,  2D photography. 
ECG will also be conducted during the screening visit.  Following completion of study 
procedures (including MRI), subjects will be randomized in order for the PI to administer 
subjects with the Rx prescription, if appropriate (i.e., Celecoxib  / cetirizi ne). 
Day 1/Baseline:  
At Baseline visit, subjects will be given with their randomized medication if appropriate. 
Subjects will receive a single multi -injection treatment of RZL -012 on Day 1.  AEs will be 
recorded.  Subjects will be asked about their pain levels using VAS. Additional 
medications/treatments, will be given according to its instructions for use.  
Day 1 -Day 84 Follow -Up Period  
Subjects will return to the site for study visits on Days 2, 4, 7, 14, 21, 28, 56 and 84 for 
efficacy and safety assessments.  
For subjects having unresolved AEs on Day 84, an unscheduled visit will be set 6 -8 weeks 
after Day 84 to verify the resolution of the AE. On that visit, follow up of using 
photographs  C -CAT and S -CAT will also be conducted.  
Subjects will be advised to continue their regular diet and physical activity during the study.  
Safety assessments include vital signs, ECG, AE s severity assessment, and treatment area 
evaluation. Treatment area evaluations including, but not limited to evaluation of edema, 
bruising, dysphasia, dysphonia, erythema, dyspigmentation, induration, numbness, pain, 
paresthesia, pruritus, skin ulceration and necro sis, injury to the marginal mandibular nerve, 
vascular and nerve injury and tissue damage to nearby vulnerable anatomic structures. 
Specifically, degree of swelling severity will be assessed as a fu nction of time and in each 
visit Subjects will be asked about their pain levels using VAS. Pain at injection site will not 
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 13 of 44 CONFIDENTIAL  
 be recorded as an AE but the information regarding pain will be obtained from the VAS 
scores completed by the subject.  Concomitant medications will be recorded.  
Sample Size  Up to 75 subjects (5 in each treatment group in stage 1 of the study and up to 10 subjects in 
each treatment group in stage 2 of the study).  
Study 
Population  Adult volunteers age 18 to 65 years who have consented to participate in this study.  
Main Inclusion 
Criteria  For a subject to be eligible for this study, he or she must meet all of the following criteria:  
1. Is a male or female subject between the ages of 18 and 65 years, inclusive.  
2. Has body mass index (BMI) between >22   kg/m2 and <40   kg/m2. 
3. Has SMF  bulge  that is contiguous and fits to 32 ±4 injections sites according to a grid 
with 1 centimeter (cm) distance between injection points.  
4. Has grade 3 to 4 of  SMF as rated by both the C -CAT and S -CAT.  
5. Has stable weight, with no fluctuation of >5 kg in the past 12 months . 
6. If female, is not pregnant or breastfeeding based on the following:  
a. agree to the use of highly effective contraceptive methods  for at least 2 weeks 
before baseline until 4 weeks after the last day of study drug and a negative 
serum pregnancy test (ß -hCG) at screening and negative urine pregnancy test at 
baseline; or  
b. is abstaining  
c. is of nonchildbearing potential defined as clinically infertile as the result of 
surgical sterilization (hysterectomy, bilateral tubal ligation, and/or bilateral 
oophorectomy); or   
d. is confirmed postmenopausal status (defined as either having amenorrhea for ≥ 
12 consecutive months without another cause or documented serum follicle -
stimulating hormone (FSH) level > 40 mIU/mL or another documented medical 
condition (e .g., was born without a uterus) ) 
NOTE: The following are considered highly effective contraceptive methods: 
hormonal oral contraceptives, injectables, and patches; intrauterine devices; 
double -barrier methods (synthetic condom, diaphragm, or cervical cap used with 
spermicidal foam, cream,  or gel); and male partner sterilization.  
7. If male (with or without vasectomy), agree to the use of highly effective contraceptive 
methods as listed above in criteria 7 as well as to use a barrier method, e.g. condom , 
from study check -in until 7 days after drug injection.  
8. Is willing to avoid strenuous exercise for seven (7) days post treatment.  
9. Is able to  adhere to the visit schedule and protocol requirements and be available to 
complete the study.  
10. Is willing and able to sign an Institutional Review Board (IRB) approved informed 
consent form (ICF) indicating that they are aware of the investigational nature of the 
study.  
Main Exclusion 
Criteria  Subjects must NOT  meet any of the following Exclusion criteria to be eligible for 
enrollment:  
1. Is unable to tolerate subcutaneous injections.  
2. Has any systemic disease including but not limited to gastritis  or ulcers, renal 
dysfunction, hypertension, liver disease, glaucoma, diabetes and/or cardiovascular 
disease , , regardless of whether the condition is controlled with medication.  
 
3. Has any contraindications to oral corticosteroids ( methylprednisolon ), NSAIDs (e.g.,  
Celecoxib ) or non -sedative antihistamines (e.g. cetirizine ) 
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 14 of 44 CONFIDENTIAL  
 4. Has skin laxity (i.e., elastosis, skin crepiness, skin redundancy, skin draping, vertical 
and/or horizontal skin bands and folds, blunting of cervical mental angle, loss of 
opposition of skin to underlying neck structures due to skin laxity) that could obs cure 
the evaluation and treatment of SMF.  
5. Has any scars, unshaven hair, tattoos, facial hair or jewelry on or near the proposed 
treatment area . 
6. Has presence of structures or confounding factors that may interfere with assessing 
SMF such as but not limited to enlarged submandibular salivary and/or parotid glands, 
micrognanthia, chin implant, soft tissue volume augmentation of chin and/or jawline, 
pronounced platysmal bands and deep necklace lines or presence of facial jowls that 
could obscure the evaluation of SMF.  
7. Has a fat bulge under the chin  that is too large to be adequately treated by 32 ±4 
contiguous injections on a 1cm grid . 
8. Has a fat bulge under the chin that is of an insufficient volume to allow 32 ±4 injections 
within a contiguous 1 cm grid.  
9. Has significant history or current evidence of a medical, psychological or other 
disorder that, in the Investigator’s opinion, would preclude enrollment in the study.  
10. Has an active bacterial, fungal, or viral infection in the proposed treatment area.  
11. Has a pre -existing skin condition in the submental region that, at the Investigator’s 
discretion, may confound evaluation or analysis.  
12. Has previously had treatments or surgery in the submentum, such as but not limited to, 
focused ultrasound, radiofrequency, cryolipolysis, liposuction, sodium deoxycholate, or 
neck lift.  
13. Has pre-existing neurological or gastrointestinal condition leading to dysphagia, 
dysphonia, or facial nerve palsy.  
14. Has Dercum’s Disease.  
15. Has allergic reactions to injectables   
16. Has allergic reactions to cetirizine  or Celecoxib.  
17. Has any pre -existing medical condition other than increased SMF that, at the 
Investigator’s discretion, may result in increased submental fullness, such as but not 
limited to, thyroid enlargement, goiter, cervical lymphadenopathy, etc.  
18. Has a planned fat reduction procedure of any variety to the submental region for the 
duration of the study.  
19. Has medication or a history of coagulopathy.  
20. Has a history or family history of venous thrombotic disease.  
21. Has been treated chronically at least three (3) months prior to study entry with systemic 
steroids or immunosuppressive drugs.  
22. Has been treated chronically at least one (1) week prior to study entry with non -
steroidal anti -inflammatory drugs (NSAIDs)  
23. Has used anticoagulation therapies that may increase bleeding or bruising (i.e., aspirin, 
ibuprofen/Celecoxib, warfarin, vitamins, and herbal preparations) for seven (7) days 
prior to treatment.  
24. Has had treatment with botulinum toxin injections in the neck or chin area within nine 
(9) months prior to screening.  
25. Current participation or participation within three (3) months prior to the start of this 
study in a drug or other investigational research study.  
26. Claustrophobia or MRI incompatible device or implant . 
Dosage and 
Administration 
of Study Drug  Subjects will receive study treatments in accordance with the treatment group to which the 
subject is randomized:  
 
 Group 1  Group 2  Group 3  Group 4  Group 5  
Day 1  RZL -012 RZL -012 + 1% 
lidocaine with RZL -012 + 
methylprednRZL -012 +  RZL -012 +  
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 15 of 44 CONFIDENTIAL  
 1:100,000 
epinephrin e 
(10  minutes  
prior to RZL -
012) 
 isolone  dose 
pack (the 
first dose of 
2 tablets 
(8mg) is 
administered
1-2 hours 
prior to 
RZL -012) 
 
A total of 24 
mg (16 mg 
after RZL -
012, as per 
IFUs)  
 200 mg 
Celecoxib 
BID and 10 
mg 
cetirizine  
BID (the 1st 
dose is 
administere
d 1-2 hours 
prior to 
RZL -012).  pressure 
garment  
Day 2    20 mg 
methylpredn
isolone  200 mg 
Celecoxib 
BID and 10 
mg  
cetirizine  
BID pressure 
garment  
Day 3    16 mg 
methylpredn
isolone  200 mg 
Celecoxib  
BID and 10 
mg 
cetirizine  
BID pressure 
garment  
Day 4    12 mg 
methylpredn
isolone  200 mg 
Celecoxib  
BID and 10 
mg Zyrtec 
BID pressure 
garment  
Day 5    8 mg 
methylpredn
isolone  200 mg 
Celecoxib  
BID and 10 
mg 
cetirizine  
BID pressure 
garment  
Day 6    4 mg 
methylpredn
isolone  200 mg 
Celecoxib  
BID and 10 
mg 
cetirizine  
BID pressure 
garment  
BID = twice daily,  
 
RZL -012 will be administered via multiple injections (32 ±4) for a  total dose of 240 ±30 mg. 
Each injection point will be dosed with 7.5 mg RZL -012 in a volume of 0.15 mL/ injection 
site. The total injection volume for all groups will be 4.8 mL ±0.6. 
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 16 of 44 CONFIDENTIAL  
 Subjects will be injected with RZL -012 perpendicularly (90°) to the skin. An ice pack will 
be placed on the injected area for pain relief immediately after injection. Subjects will 
remain seated in the injection position for an additional 10 minutes after dosing.  
The injection pattern will be based on a submental area shaped grid in which the distance 
between rows and columns will be 1 cm, as seen in the figure below. The Investigator will 
choose 32 ±4 sequential points on the grid that will mark the injected area according to SMF 
fullness and convexity. The treatment area boundary: superiorly by a line 1 cm inferior to 
the mandibular margin, laterally by the sternocleidomastoid muscles, and inferiorly by the 
hyoid bone.  
 
 
Safety Analysis  AEs will be collected and reviewed to evaluate the safety and tolerability of RZL -012. AE 
collection will begin after dosing and will end at on Day 84. For subjects having  unresolved 
AEs on  Day 84, an unscheduled visit will be set 6 -8 weeks after Day 84 to verify the 
resolution of the AE.   
Other safety measures will include vital sign measurements, laboratory parameters, ECG, 
and treatment area evaluation  including, but not limited to evaluation of edema, bruising, 
dysphasia, dysphonia, erythema, dyspigmentation, induration, numbness, pain, paresthesia, 
, pruritus , skin ulceration and necrosis, injury to the marginal mandibular nerve, vascular 
and nerve injury and tissue damage to nearby vulnerable anatomic structures.  Specifically, 
swelling severity will be assessed in each visit, subjects will be asked about their pain 
levels. Pain at injection site will not be recorded as an AE but the information regarding 
pain will be obtained from the VAS scores completed by the subject.  AEs related to nerve 
injury will be AEs of special interest. Concomitant medications will be recorded.  
Statistical 
Analysis  All measured variables and derived parameters will be listed individually and, if 
appropriate, tabulated by descriptive statistics.  
For categorical variables, summary tables will be provided giving sample size, absolute and 
relative frequency, and 95% confidence interval (CI) for proportions by study arm.  
For continuous variables, summary tables will be provided giving sample size, arithmetic 
mean, standard deviation, coefficient of variations (CV%), median, minimum and 
maximum, and 95% CI for means of variables by study arm.  
Primary endpoint  and exploratory endpoints  will be analyzed in descriptive manner.  
 The data will be analyzed using the SAS version 9.4 (SAS Institute, Cary North Carolina).  
Study Duration  It is planned that each subject will participate in the study for 4  months, which comprises a 
screening period, baseline/treatment period, and follow up period.  
Study Centers  6 clinical centers  
 
  

Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 17 of 44 CONFIDENTIAL  
  
1.2 Schedule of Activities  
 Study Procedure  Screening  Baseline  
(Treatment)  Post Baseline Visit Schedule  
Study Day  Day (-28) 
through 
Day ( -1) Day  1  Day 2  Day 4  Day 
7 Day 
14 Day 
21 Day 
28 Day 
56 Day 
84 
Signed informed 
consent  X          
Medical history  X          
Physical Exam  X    X     X 
Concomitant 
Medication  X X X X X X X X X X 
Pregnancy ß -hCG  X          
Pregnancy urine 
test (women)   X        X 
Weight  
measurements  X X      X  X 
Height 
measurement  X          
Biochemistry Lab 
parameters  X  X  X   X  X  
ECG  X    X     X  
Vital signs  X Pre X post X X X X X X X X 
Randomization  X          
Injection of RZL -
012  X         
Clinician Chin 
Assessment Tool 
(C-CAT)  X X      X X X 
Subject - Self-
Chin Assessment 
Tool (S -CAT)  X X      X X X 
Subject’s 
Satisfaction 
questionnaire for 
SMF appearance  X       X X X 
2D Standardized 
photography  X  X X X X X X X X 
MRI  X         X 
AEs including 
VAS   X X X X X X X X X 
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 18 of 44 CONFIDENTIAL  
 2.0 INTRODUCTION  
1.1. Study Rationale  
The recent clinical study (RZL -012-SMF -P2b-US-001) was a double -blind, randomized, three -
arm, placebo -controlled Phase 2b study  that tested the efficacy and safety of RZL -012 injections 
into the submental fat in 151 subjects. Single administration of high dose RZL -012 (50mg/ml) 
result ed in a clinically meaningful reduction in submental fat. The efficacy of the RZL -012 high 
dose was higher than that of the low dose  and of the placebo . Local injection -site reactions were 
the most commonly reported AEs with injection -site pain, nodules induration and edema being 
clearly RZL -012 related. Injection -site severe swelling in the submental area was shown to be 
associated with additional AEs such as dysphagia, dysphonia, and dyspnea.  
This clinical trial will  assess ways to reduce AEs related to swelling and pain.  
1.2. Scientific Background  
RZL -012 is a cytolytic drug - it disrupt s cell membrane integrity which result s in necrotic cell 
death. RZL -012 demonstrated a cell killing effect on cultured adipocyte, fibroblasts and HepG2 
cells with IC 50 values ranging between 20 -100 µM. In vivo pig studies demonstrated liponecrosis 
at the injection site, followed by a transient inflammatory response and finally, a healing process 
in which fibrotic tissue replaces previous fat tissue.  Necrosis of fat tissue at the injection site was 
seen as early as 24 hours after injection and was still evide nt 2 weeks later but completely cleared 
by 12 weeks post dosing. A macrophage -mediated inflammatory response was also prominent at 
24 hours and 14 days after injection with only minimal signs of inflammation remaining by 12 
weeks post dosing. Fibrosis show ed a different pattern compared with liponecrosis and 
inflammation, starting at 14 days post dosing and becoming much more prominent at 12 weeks 
post dosing. In essence, RZL -012 enable d de-novo generation of fibrotic  tissue to replace excess 
fat tissue at selected  anatomical sites . 
To date, Raziel has conducted several clinical studies under INDs to evaluate the safety and 
efficacy of RZL -012 for local fat reductions, including obesity (INDs 119941, 133324), lipomas 
of Dercum’s Disease patients and SMF (IND 135762) and SMF and flank reduction (IND 154260). 
Across all clinical trials approximately 222 subjects have received single doses of RZL -012 
ranging from 5  mg to 412 mg per subject.  
1.2.1.  Non-Clinical  Studies  
The mechanism of action of RZL -012 has been studied in in -vitro studies and in in -vivo studies in  
pigs (domestic Yorkshire crossbred swine ). Pigs were chosen for these studies because their 
subcutaneous  fat resembles that of humans. RZL -012 injected into SC pig fat first caused 
liponecrosis at the injection site, followed by a transient inflammatory response and finally by a 
healing process in which fibrotic tissue replaced previous fat tissue.  
Safety pharmacology studies of RZL -012 in male Sprague Dawley rats  demonstrated that  RZL -
012 has no effects  on the  central nervous system functions , or on the respiratory system, on  ECG 
parameters or blood pressure .  Safety pharmacology studies of RZL -012 in domestic Yorkshire 
crossbred swine  demonstrated no effect s on ECG parameters or blood pressure.  
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 19 of 44 CONFIDENTIAL  
 Single and chronic toxicology studies were conducted in  Sprague -Dawley rats  and in pigs. Local, 
dose-related skin reactions included fibrosis, inflammation, degeneration/necrosis, atrophy and 
epidermal hyperplasia . Systemic reactions included increased blood urea nitrogen [BUN ], 
increased creatinine and aspartate aminotransferase [AST] levels and histopathological changes in 
kidneys (necrosis in tubular epithelium) . 
Rat embryo -fetal development (EFD) and fertility and early embryo -fetal development (FEED; 
fertility) studies demonstrated no changes on fertility and reproduction in males and females . 
Further details on mechanism of action, safety pharmacology, and toxicology of RZL -012 are 
provided in the  investigator’s brochure  (IB). 
1.2.2.  Clinical Studies  
To date, approximately 222 subjects have received single doses of RZL -012 ranging from 5  mg 
to 412 mg per subject  across 8 clinical trials ( Table 1). 
Table 1 Estimated Cumulative Exposure from Clinical Studies  
Study  Number  Study  Population  RZL -012 Placebo  
N Dose (mg)  N 
RZL -012-P0-US-001 Healthy  Subjects  (Phase  0 obesity)  18 5-20 6 
RZL -012-P2a-US-001 Healthy  subjects  (Phase  2a obesity)  24 40-180 7 
RZL -012-FD-P2a-US-001 Lipedema  (Phase  2a) 6 60-80 0 
RZL -012-FD-P2a-US-001 DD (Phase  2a) 6 30-40 0 
RZL -012-DD-P2b-US-001 DD (Phase2b)  29 40-240 18 
RZL -012-SMF -P2a-US-001 Submental  Fat (Phase  2a) 18 70-210 10 
RZL -012-hADMEC14 -001 Human  ADME study  6 72.9 0 
RZL -012-SMF -P2b-US-001 Submental  Fat (Phase  2b) 103 142-270 48 
RZL -012-FL-P2US -001 Subjects with Flank Fat  12 412 0 
 Overall  Total  Number  of Subjects  222 - 89 
All clinical trials were conducted in the US, and in all trials RZL -012 was administered via 
multi ple injections during a single injection session.  
1.2.2.1.  Clinical Trials  in SMF  
Three  clinical trials have been conducted to assess the efficacy and safety of RZL -012 in reducing 
fat in the submental area. One trial (study RZL -012-SMF -P2a-US-001)  was a single -blind, 
randomized, placebo -controlled, phase 2a, 2 -cohort study. The second trial (study RZL -012-SMF -
P2b-US-001)  was a double -blind, randomized, three -arm, placebo -controlled Phase 2b study . Both 
studies were completed. The third trial (S tudy RZL -012-SMF C-P2-US-001) is An Open -Label 
Phase 2 Study to Compare the Pharmacokinetics, Efficacy and Safety of  
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 20 of 44 CONFIDENTIAL  
 RZL -012 in Chinese Subjects Seeking Submental Fat Reduction vs. Non -Chinese Subjects 
Seeking Submental Fat Reduction . Study enrollment  has been initiated recently .  
Study RZL -012-SMF -P2a-US-001 
Study RZL -012-SMF -P2a-US-001.2 was a single -blind study conducted in 28 subjects with 
submental fat. An assessment of efficacy was based on the Physician global assessment scale, SMF 
volume  change (MRI) , and subject's Face -Q satisfaction questionnaire.  
All subjects received a single dosing session and were followed up for 84 days. RZL -012 low dose  
(N=8)  received  an average injected dose of 80 mg/subject , RZL -012 high dose  (N=10)  an average 
injected dose of 158.5  mg/subject . Ten subjects received placebo . Based on a physician global  
assessment scale  (physicians were not blinded to  study  treatment ), 17/18 of RZL -012 treated 
subjects demonstrated an improvement in submental fat appearance on  84 days after  treatment vs. 
baseline . None of the placebo subjects demonstrated any change in submental fat  appearance on 
Day 84 vs. baseline . According to the Subject Face -Q Questionnaire (subjects were blinde d to 
study treatment ), subjects  reported  satisf action regarding perceived effects of RZL -012 on 
submental fat appearance . The RZL -012 low dose group had  a 2.4-fold increase in mean subject 
satisfaction  score, the RZL -012 high dose  group  showed a 2.5 -fold increase in mean subject 
satisfaction  score while the p lacebo group  did not demonstrate an improvement in satisfaction on 
Day 84 vs. baseline.  These  Clinician Reported Outcome ( CRO ) and Patient Reported Outcome 
(PRO ) were correlated with the objective measu re of MRI , determined  on Day 84  vs. baseline . 
The high dose RZL -012 group showed  a volume reduction of -22.2%  ± 14.9 (p<0.05 vs the placebo 
group),  the low dose RZL -012 group showed  a volume reduction of -10.6%  ± 14.5 (p=0.67 vs the 
placebo group, NS) and the placebo group demonstrated a volume reduction of -0.4%  ± 13.9.  
Study RZL -012-SMF -P2b-US-001 
Study RZL -012-SMF -P2b-US-001 was a double -blind, randomized, three -arm, placebo -controlled 
Phase 2b study conducted in 151 subjects with submental fat.  Forty -eight subjects were 
randomized to the placebo group, 53 subjects to the RZL -012 low dose ( 183.6  mg) group and 50 
subjects to the RZL -012 high dose (270 mg) group. An assessment of efficacy was based on the 
Clinician Assessment Tool (C -CAT ), Subject Self -Chin Assessment Tool (S -CAT); and SMF 
volume  via MRI  and caliper -measured submental thickness . Raziel met the primary and secondary 
endpoints of the study. The proportion of subjects that had an improvement of at least 1 grade  
using the C -CAT and proportion of subjects who had an improvement of at least 2 grades in both 
C-CAT and S -CAT  in the same subjec t were statistically significant ly higher  in RZL -012 high 
dose vs. placebo .  The MRI results demonstrated a volume reduction of -14.9%, -8.3% and no 
reduction in volume in RZL -012 high dose, low dose and placebo, respectively. Results were 
statistically significant.  
1.3. Risk -Benefit Assessment  
1.3.1.  Identified RZL -012 Risks  
Adverse Events  
Identified risks are local injection -site reactions including injection -site bruising, induration, 
edema, pain, and erythema which are commonly reported after injection of RZL -012. Most 
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 21 of 44 CONFIDENTIAL  
 injection site reactions are transient and are not observed for more than 28 -56 days following 
injection. None of these identified risks are serious in nature.  
Submental swelling and dysphagia have also been identified as common risks. These two are 
transient and have not been  serious in nature.   
In addition, nerve damage was also reported in association with RZL -012 treatment. While these 
AEs should be carefully monitored, it is noted that there were no serious outcomes to any of these 
events and all were short -lived.  
Laboratory - D-Dimer  
Treatment with RZL -012 causes a transient increase in D -dimer without any clinically significant 
activation of the coagulation system nor any presence of Disseminated Intravascular Coagulation 
(DIC). The absence of any clinical symptoms related to elevatio n of D -dimer supports a direct link 
between RZL -012 induced inflammation and elevated D -dimer levels, unrelated to venous 
thromboembolic disease.  
Laboratory – ALT and AST  
RZL -012 is associated with a transient increase in AST which is  seen as early as one day following 
RZL -012 treatment and ha s resolved by 7 days post -treatment. It is noted that the increase has not 
been associated with any increases in other liver enzymes, nor with any clinical symptoms , other 
than in one subject i n study RZL -012-P0US -01.3, who received  a small single dose of 20 mg of 
RZL -012. This subject  demonstrated a significant transient increase in alanine aminotransferase 
(ALT) blood levels (Levels had x7 -9-fold increase from the upper limit of normal (ULN) on Days 
14 and 21, respectively) and a moderate elevation of aspartate aminotransferase (AST) blood levels 
(~4 fold increase from ULN) 14 days following injection of the highest dose of active treatment 
(20 mg/subject). Resolution for AST elevated levels and reduction for ALT levels to Grade 1 
(mild), occurred 14 days following detection (i.e. 28 d ays after dosing). ALT levels were normal 
on the next visit on Day 56. Other liver enzymes such as GGT and alkaline phosphatase, as well 
as bilirubin levels remained within normal range.  
The relationship between RZL -012 injection and a potential increase in liver enzymes is not 
completely understood. In preclinical studies which were conducted by Raziel, a rise in AST 
enzyme levels was observed in the high doses female rat group (20 mg/rat  (about 80 mg/kg), 
equivalent to a human dose >900 mg/subject), returning to normal levels within 14 days of 
recovery. Raziel Therapeutics continues to monitor closely for any changes in liver enzymes.  
1.3.2.  Benefits  
The cytolytic effect of RZL -012 has been demonstrated in non -clinical in -vitro and in -vivo studies. 
When administered into subcutaneous tissue, this cytolytic effect translates into a reduction in 
subcutaneous tissue. The reduction in submental fat has bee n demonstrated in Phase 2a and Phase 
2b studies. Confirmatory Phase 3 studies will be conducted.  
 
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 22 of 44 CONFIDENTIAL  
 3.0 STUDY OBJECTIVES  AND ENDPOINTS  
3.1 Study Objectives  
3.1.1 Primary Objective  
• The primary objective of this study is to compare the benefits of lidocaine, methylprednisolone ,  
Celecoxib +  cetirizine  or compression garments  on RZL -012-induced adverse events . 
3.1.2 Secondary Objectives  
• To assess the safety profile of RZL -012 of combining lidocaine, methylprednisolone  ,  Celecoxib 
+ cetirizine  or compression garment with RZL -012 
3.2 Study Endpoints  
3.2.1 Primary Endpoint  
• Safety profile of combining lidocaine, methylprednisolone  ,  Celecoxib +cetirizine or a 
compression garment with RZL -012. 
3.2.2 Exploratory  Endpoints  
The secondary endpoints for the study are: 
• Proportion of subjects  who have at least a 1 -grade improvement in the C -CAT on Day 84 
versus baseline in subjects receiving RZL -012 alone or in combination with other 
medications.  
• Proportion of subjects  who have at least a 1 -grade improvement in the S -CAT on Day 84 
versus baseline in subjects receiving RZL -012 alone or in combination with other 
medications.  
• Proportion of subjects  who have at least a 1 -grade improvement in both C -CAT and S -CAT 
on Day 84 versus baseline in subjects receiving RZL -012 alone or in combination with other 
medications.  
• Proportion of subjects  who have at least a 2 -grade improvement in both C -CAT and S -CAT 
on Day 84 versus baseline in subjects receiving RZL -012 alone or in combination with other 
medications.  
• Changes in SMF volume measured by MRI scans on Day 84 versus baseline in subjects 
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 23 of 44 CONFIDENTIAL  
 receiving RZL -012 alone or in combination with other medications.  
• Satisfaction in subjects receiving RZL -012 alone or in combination with other medications . 
4.0 STUDY  DESIGN  
4.1 Overall Design  
This is a Phase 2, open -label, 2 -stage, adaptive -design study in which subjects will be randomized 
into one of 5 treatment groups comprised of RZL -012 with or without additional study treatments:  
1. RZL -012 alone  
2. RZL -012 and 1% lidocaine with 1:100,000 epinephrine (on Day 1) – 5ml lidocaine will be 
injected 10 minutes before RZL -012 treatment . 
3. RZL -012 and oral methylprednisolone  dose pack (8  mg (2 tablets) on Day 1 before treatment 
followed by 16 mg after treatment (as per Instructions for Use)). From Day 2, a daily tapering off 
by 4 mg until Day 6 will be administered per Rx Instructions for use.  
4. RZL -012 and Celecoxib and cetirizine  (200 mg Celecoxib BID and 10 mg cetirizine  BID on Days 
1, 2, 3, 4, 5 and 6) . 
5. RZL -012 + sling/pressure garment (until Day 6) . 
In the first stage of the study, 5 subjects will be randomized into each of the treatment groups. 
Study outcomes will be assessed up to one week thereafter to determine the need to modify 
additional study treatments. Subsequently up to 10 additional subjec ts will be randomized into 
each of the treatment groups for the second  stage   of the study.   
For each subject, the study will consist of a screening period, baseline period in which subjects 
will receive a single treatment session of RZL -012 with the assigned treatment and a follow -up 
period.  RZL -012 will be administered during a single treatment session via multiple injections 
into the submental area under the chin. Subjects will thereafter be monitored for safety and efficacy 
for at least 84 days.  
Each subject will be treated with the same dose of RZL -012 :  
• RZL -012 (concentration of injected solution 50 mg/mL RZL -012) of 7.5 mg/0.15 
mL/injection point that results in a total dose/volume of 240±30mg mg/4.8±0.6 mL RZL -
012, 
Each subject will receive additional study treatments in accordance with the treatment group to 
which the subject is randomized . 
4.2 Rationale for Study Design  
Because there are 5 different treatment arms, and subjects receive different additional study 
treatments depending on the treatment arm to which the subject is randomized, blinding of study 
treatments would be difficult. Therefore, the study will employ an open -label design.  
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 24 of 44 CONFIDENTIAL  
 4.3 Rationale for Study Dose  
The Phase 2b study ( RZL -012-SMF -P2b-US-001) demonstrated that a single treatment session of 
RZL -012 at a maximal dose of 270 mg into the subcutaneous tissue of the submental area reduces 
fat and improves appearance of this area.  Therefore, Raziel intends to proceed with this dose into 
Phase 3 clinical trials.  
5.0 STUDY  POPULATION  
5.1 Inclusion Criteria  
For a subject to be eligible for this study, he or she must meet all of the following inclusion 
criteria:  
1. Is a male or female subject between the ages of 18 and 65 years, inclusive.  
2. Has body mass index (BMI) between >22  kg/m2 and <40  kg/m2.  
3. Has SMF  bulge that is contiguous and fits to 32±4 injections sites according to a grid with 1 
centimeter (cm) distance between injection points.  
4. Has grade 3 to 4 of SMF as rated by both the C -CAT and S -CAT.  
5. Has stable weight, with no fluctuation of >5 kg in the past 12 months.  
6. If female, is not pregnant or breastfeeding based on the following:  
agree to the use of highly effective contraceptive methods  for at least 2 weeks before baseline until 4 weeks after 
the last day of study drug and a negative serum pregnancy test (ß -hCG) at screening and negative urine pregnancy 
test at baseline; or  
is abstaining  
is of nonchildbearing potential defined as clinically infertile as the result of surgical sterilization (hysterectomy, 
bilateral tubal ligation, and/or bilateral oophorectomy); or   
is confirmed postmenopausal status (defined as either having amenorrhea for ≥ 12 consecutive months without 
another cause or documented serum follicle -stimulating hormone (FSH) level > 40 mIU/mL or another 
documented medical condition (e .g., was born without a uterus) ) 
NOTE: The following are considered highly effective contraceptive methods: hormonal oral contraceptives, 
injectables, and patches; intrauterine devices; double -barrier methods (synthetic condom, diaphragm, or cervical 
cap used with spermicidal foam, cream,  or gel); and male partner sterilization.  
7. If male (with or without vasectomy), agree to the use of highly effective contraceptive methods 
as listed above in criteria 7 as well as to use a barrier method, e.g. condom , from study check -
in until 7 days after drug injection.  
8. Is willing to avoid strenuous exercise for seven (7) days post treatment.  
9. Is able to adhere to the visit schedule and protocol requirements and be available to complete 
the study.  
10. Is willing and able to sign an Institutional Review Board (IRB) approved informed consent 
form (ICF) indicating that they are aware of the investigational nature of the study.  
 
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 25 of 44 CONFIDENTIAL  
 5.2 Exclusion Criteria  
Subjects must NOT  meet any of the following exclusion criteria to be eligible for enrollment:  
1. Is unable to tolerate subcutaneous injections  
2. Has any systemic disease including but not limited to gastritis  or ulcers, renal dysfunction, 
hypertension, liver disease, glaucoma, diabetes and/or cardiovascular disease , regardless of 
whether the condition is controlled with medication . 
3. Has any contraindications to oral corticosteroids (prednisone), NSAIDs (e.g.,  Celecoxib) or 
non-sedative antihistamines (e.g. cetirizine ) 
4. Has skin laxity (i.e., elastosis, skin crepiness, skin redundancy, skin draping, vertical and/or 
horizontal skin bands and folds, blunting of cervical mental angle, loss of opposition of skin to 
underlying neck structures due to skin laxity) that could obs cure the evaluation and treatment 
of SMF.  
5. Has any scars, unshaven hair, tattoos, facial hair or jewelry on or near the proposed treatment 
area.  
6. Has presence of structures or confounding factors that may interfere with assessing SMF such 
as but not limited to enlarged submandibular salivary and/or parotid glands, micrognanthia, 
chin implant, soft tissue volume augmentation of chin and/or jawline, p ronounced platysmal 
bands and deep necklace lines or presence of facial jowls that could obscure the evaluation of 
SMF.  
7. Has a fat bulge under the chin that is too large to be adequately treated by 32±4 contiguous 
injections on a 1cm grid .  
8. Has a fat bulge under the chin that is of an insufficient volume to allow 32±4 injections within 
a contiguous 1 cm grid.  
9. Has significant history or current evidence of a medical, psychological  or other disorder that, 
in the Investigator’s opinion, would preclude enrollment in the study.  
10. Has an active bacterial, fungal, or viral infection in the proposed treatment area.  
11. Has a pre -existing skin condition in the submental region that, at the Investigator’s discretion, 
may confound evaluation or analysis.  
12. Has previously had treatments or surgery in the submentum, such as but not limited to, focused 
ultrasound, radiofrequency, cryolipolysis, liposuction, sodium deoxycholate, or neck lift.  
13. Has pre -existing neurological or gastrointestinal condition leading to dysphagia, dysphonia, or 
facial nerve palsy.  
14. Has Dercum’s Disease.  
15. Has allergic reactions to injectables  
16. Has allergic reactions to cetirizine  or Celecoxib.  
17. Has any pre -existing medical condition other than increased SMF that, at the Investigator’s 
discretion, may result in increased submental fullness, such as but not limited to, thyroid 
enlargement, goiter, cervical lymphadenopathy, etc.  
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 26 of 44 CONFIDENTIAL  
 18. Has a planned fat reduction procedure of any variety to the submental region for the duration 
of the study.  
19. Has medication or a history of coagulopathy.  
20.  Has a history or family history of venous thrombotic disease.  
21. Has been treated chronically at least three (3) months prior to study entry with systemic steroids 
or immunosuppressive drugs.  
22. Has been treated chronically at least one (1) week prior to study entry with non -steroidal anti -
inflammatory drugs (NSAIDs)  
23. Has used anticoagulation therapies that may increase bleeding or bruising (i.e., aspirin, 
ibuprofen/Celecoxib, warfarin, vitamins, and herbal preparations) for seven (7) days prior to 
treatment.  
24. Has had treatment with botulinum toxin injections in the neck or chin area within nine (9) 
months prior to screening.  
25. Current participation or participation within three (3) months prior to the start of this study in 
a drug or other investigational research study.  
26. Claustrophobia or MRI incompatible device or implant.  
6.0 STUDY  INTERVENTION  
6.1 Study Intervention Administration  
6.1.1 Study Interv ention Description  
RZL -012 is provided as a sterile liquid solution suitable for injection.  It has a concentration of 
50 mg/mL.  It is packaged in glass vials  and supplied in study kits . 
Subjects will be treated with additional  planned  treatments in accordance to their randomization 
group . In case subjects will be assigned to group 2, they will be injected with 5 m L lidocaine with 
1:100,000 epinephrine. In case subjects will be randomized to group 3 or 4 they will receive a 
prescription to buy in the pharmacy the relevant drugs , i.e. methylprednisolone  dose pack (if assigned 
to group 3) and Celecoxib and cetirizine  (in case assigned to group 4) . This is in order to allow them 
to take the drugs at baseline visit (Day 1) prior to RZL -012 in jection.  Subjects will take medicines 
1-2 hours prior to RZL -012 injection and continue after RZL -012 injection per instructions for use 
for each of the medicines for a total period of 6 days.  If subjects are randomized to group 5, they 
will be given with the pressure garment in the site  immediately after injection and will wear the 
garment up to day 6 after injected.  Description of group assignments is described in Table 2.  
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 27 of 44 CONFIDENTIAL  
 Table 2– Study Group Treatment  
 Group 1  Group 2  Group 3  Group 4  Group 5  
Day 1  RZL -012 RZL -012 + 1% 
lidocaine with 
1:100,000 
epinephrin e (10  
minutes  prior to 
RZL -012) 
 RZL -012 +  
methylprednisolone  
dose pack (the first 
dose of 2 tablets 
(8mg) is 
administered1 -2 
hours prior to RZL -
012) 
 
A total of 24 mg 
(16 mg after RZL -
012, as per IFUs)  
 RZL -012 +  
200 mg 
Celecoxib BID 
and 10 mg 
cetirizine  BID 
(the 1st dose is 
administered 1 -2 
hours prior to 
RZL -012).  RZL -012 +  
pressure 
garment  
Day 2    20 mg 
methylprednisolone  200 mg 
Celecoxib BID 
and 10 mg  
cetirizine  BID pressure 
garment  
Day 3    16 mg 
methylprednisolone  200 mg 
Celecoxib  BID 
and 10 mg 
cetirizine  BID pressure 
garment  
Day 4    12 mg 
methylprednisolone  200 mg 
Celecoxib  BID 
and 10 mg 
cetirizine  BID pressure 
garment  
Day 5    8 mg 
methylprednisolone  200 mg 
Celecoxib  BID 
and 10 mg 
cetirizine  BID pressure 
garment  
Day 6    4 mg 
methylprednisolone  200 mg 
Celecoxib  BID 
and 10 mg 
cetirizine  BID pressure 
garment  
BID = twice daily,  
Subjects will undergo a single treatment session with maximum 36 injections  of 7.5  mg RZL -012 
each for a total RZL -012 dose of 270 mg. The total injection volume for all groups will be 4.8 
mL±0.6.  
Subjects will be injected with RZL -012 perpendicularly (90°) to the skin. An ice pack will be 
placed on the injected area for pain relief immediately after injection. Subjects will remain seated 
in the injection position for an additional 10 minutes after dosing.  
The injection pattern will be based on a submental area shaped grid in which the distance between 
rows and columns will be 1 cm, as seen in Figure 1 below. The Investigator will choose 32±4 
sequential points on the grid that will mark the injected area according to SMF fullness and 
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 28 of 44 CONFIDENTIAL  
 convexity. The treatment area boundary: superiorly by a line 1 cm inferior to the mandibular 
margin, laterally by the sternocleidomastoid muscles, and inferiorly by the hyoid bone.  
Figure 1 Submental Injection Pattern  
 
6.2 Preparation/Handling/Storage/Accountability  
The RZL -012 solution is supplied ready to use . The RZL -012 kits , each comprised of 2 vials, 
should be  stored in the site pharmacy or clinic at monitored room temperature conditions (22  ± 7 
°C) and protected from light.  They should be kept in a secure location physically separated from 
standard clinic or office drug supplies.  
RZL -012 is administered to the subject on the study site by the study investigator.  The vials should 
be manually shaken prior to injection.  
The following procedures prior to injection into the SMF will be applied:  
1. The lower face and anterior neck will be cleaned with an appropriate topical antiseptic.  
2. Ice/cold pack or topical local anesthesia (i.e., lidocaine cream) may be used prior to drug 
administration to enhance subject’s comfort.  
3. The treatment area will be bounded superiorly by a line 1 cm inferior to the mandibular 
margin, laterally by the sternocleidomastoid muscles, and inferiorly by the hyoid bone.  
4. Injection grid pattern will be applied by pressing the grid firmly onto the clean, dry skin, 
with the printed grid pattern facing the skin. The grid paper backing will be thoroughly 
wetted with a cotton pad soaked with sterile water. After 15 seconds, the grid cover will 
be peeled off.  
5. An area of 32±4 adjacent injection points will be determined following the Investigator’s 
evaluation.  
6. Syringes will be filled with 1  mL RZL -012 and the number of syringes will be compatible 
with the total volume of injection. Up to six (6) syringes for a total volume of 5.4 mL will 
be used.  

Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 29 of 44 CONFIDENTIAL  
 7. All injections will be administered perpendicularly in 90 degrees, using a 1 mL Luer -lock 
syringe and a 29G or 27G  x 1/2” needle, respectively.  
8. The hole of the needle should be pointing into the middle of fat layer and the injection 
direction should be towards the earth. An attempt to pull the plunger should be made prior 
to injecting to ensure no blood is coming out. If so, the plunger should be pushed down to 
inject 0.15 ml the medicine. The formulation i s viscous; therefore, resistance is expected 
during injection.  
9. Immediately following completion of the injections, an ice/cold pack will be applied for 
immediate pain relief. It will be held by the subject for at least two (2) minutes.  
10. The Investigator will record the number of injections administered for each subject.  
The injection pattern used will be based on an existing grid in the shape of the submental area, 
where distance between injection rows will be 1 cm and distance between the injection columns 
will be 1 cm.   
The number of injections for each subject will be determined by the Investigator according to 
fullness of SMF but will not be lower than 28 injections or higher than 36 injections. Total injection 
volume and number of injection per subject should be recorded on medical records.  
All study drug received by the Investigator will be inventoried and accounted for in a Dispensing 
Log. 
A maximal of 2  vials will be used for each subject. All open vials will be kept until the end of 
study when the Sponsor will determine if study drug should be returned or destroyed.   
6.3 Study Intervention Compliance  
Study treatment consists of a single administration session administered by the study investigator.  
6.4 Prior and Concomitant Medications  
Concomitant medications are defined as medications taken any time after the start of dosing until 
discharge assessments. All concomitant medication, including blood and blood products, dietary 
supplements, and non -prescription drugs , will be listed at screening/baseline. Each entry will 
include the treatment's start date, treatment name ( generic), reason for use, dosing regimen (dose 
and frequency of use), route of administration, and stop date (if applicable). Study subjects will be 
routinely questioned fo r changes in the administration of concomitant medication during the trial 
and changes should be updated from medical records as well . 
7.0 STUDY  INTERVENTION  DISCONTINUATION  
A premature discontinuation from study will occur when a subject who signed informed consent 
ceases participation in this study, regardless of circumstances, prior to completion of the protocol. 
Subjects can be prematurely discontinued from the study for o ne of the following reasons:  
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 30 of 44 CONFIDENTIAL  
 • Failure to meet inclusion/exclusion criteria before receiving first dose of study drug has 
been administered  
• Death  
• Significant safety event that in the opinion of the Investigator warrants discontinuation . 
Raziel will attempt to follow up all subjects for safety.  
• Lost to follow -up after every attempt has been made to contact the subject, including 
sending a registered letter  
• Subject withdraws consent  
The Principal Investigator and the Institutional Review Board/Ethics Committee (IRB/EC) reserve 
the right to prematurely terminate the study in the interest of subject safety and welfare. The 
Sponsor reserves the right to prematurely terminate the study at  any time for administrative 
reasons.  
8.0 STUDY ASSESSMENTS AND PROCEDURES  
8.1 Medical History  
A medical history will be obtained at screening.  Subject’s medical history should be fully 
documented to confirm study eligibility. Medical history must include, but not limited to, past and 
present medical conditions, concomitant non -drug treatments, and  hypersensitivity to drugs.  
8.2 Height  
Height will be measured at screening.  It will be reported in centimeters. A subject’s height together 
with weight will be used to calculate a subject’s BMI.  
8.3 Weight  
Body weight will be measured at screening, baseline (day 1) and at the study visit  Day 28  and 
study visit Day 84. Weight will be reported in kilograms (kg). A subject’s weight at screening 
together with height will be used to calculate a subject’s BMI.  
8.4 Pregnancy Tests  
A serum (ß -hCG) pregnancy test will be administered to females of childbearing potential at 
screening and a urine pregnancy test will be administered at baseline prior to dosing. Additional 
serum pregnancy tests will be done at any time during the study (u p to Day 84 ), if pregnancy is 
suspected.  Urine pregnancy test will be done to females of childbearing potential on Day 84.  
8.5 Complete Physical Examination  
The Investigator  (or medically qualified nominee)  will perform a complete physical exam ination  
at screening  and on Day 7 and  Day 84 visit .  
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 31 of 44 CONFIDENTIAL  
 8.6 Clinician -Chin  Assessment  Tool  (C-CAT)  
SMF ratings using the C -CAT will be conducted by a fixed and well-trained  Investigator at 
screening and baseline  (Day 1)  and at study visits on Days 28, 56, and 84 to assess the change in 
SMF severity before and following treatment.  
The C -CAT score will be based on the Investigator’s clinical evaluation of the subject in the 
Frankfurt horizontal plane. Clinical evaluation will include palpation of the chin and neck area, 
anterior, oblique and profile views of the chin and neck, and ob servation of pronation, supination, 
and lateral movement of the head. The score will be determined using the rating scale definitions. 
The score will be recorded as a whole number. At screening, the score will be used in conjunction 
with inclusion criteria . 
The C -CAT is defined below. The scale is A 5 -point scale (scored 0 -4). 
The grading system categorizes 3 aspects of submental chin fat: bulge, (size of the submental fat 
bulge) neck (extension of the bulge into the neck, downward and lateral) and jawline (the 
appearance of the jawline, presence of fat and definition of the jaw line).  
Each grade contains a description and a line drawing. Each grade is distinct and non -overlapping.  
A comprehensive  training  guide  with representative  photographic  examples  and line drawing  to 
each grade will be provided to the study center sites for training and visual comparison.  
Table 3 Clinician Chin Assessment Tool (C -CAT)  
 
8.7 Subject  – Self-Chin  Assessment  Tool  (S-CAT)  
SMF  ratings  using  the S-CAT  will be conducted  by the subject  at screening  and baseline  (Day 1)  
and at study visits on Days 28, 56, and 84 to assess the change in SMF area following treatment.  

Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 32 of 44 CONFIDENTIAL  
 The scale  has 5 grades  from  0 to 4. Each  grade  utilizing  line-drawings  and descriptors  to identify 
5 unique and non -overlapping grades.  
The chin fat is categorized  by the following  features:  bulge  (size  of the fat bulge)  neck  (extension 
of the bulge downward and laterally into the neck) and jawline (presence of fat and definition of 
the jawline).  
Self evaluations should be made sitting in an upright position with the chin at a right angle (as 
illustrated  in the line drawings).  Mirrors  will be used to see the chin,  neck  and jawline  from  both 
front and side views.  
A comprehensive  training  guide  with representative  photographic  examples  and line drawing  to 
each grade will be provided to the subjects.  
Table 4 Self Chin Assessment Tool (S -CAT)  
 
 
8.8 Magnetic Resonance Imaging (MRI)  
The purpose of the MRI exam is to evaluate whether the additional treatments (i.e., lidocaine, 
Celecoxid, Zyrtic  etc.) affects the fat reduction following treatment of RZL -012. MRI exams will 
be conducted in imaging centers close to selected clinical sites.  
MRI will be conducted at screening in order to establish a baseline value for assessment of 
treatment efficacy. Post -treatment period MRI will be completed within 84 days (± 14 days) after 
the treatment session.  
Quantitative measurements such as fat volume of the SMF area will be used as an objective 
parameter for measurement of SMF reduction following treatment.  
Sagittal 2D and 3D images of the head and neck (chin area) will be obtained using 1.5 Tesla 
machine (General Electric, Siemens, Phillips or other). For each MRI visit, the total imaging time 
is expected to be approximately thirty (30) minutes.   
 

Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 33 of 44 CONFIDENTIAL  
 During the imaging, subjects will be positioned in Head first Supine recumbent. Images in the 
sagittal plane across the entire submental region will be collected using an appropriate MR 
sequence to minimize the effects of air cavities, dental implants, and  amalgam on the resultant MR 
image. This imaging approach will generate a 2D and 3D image data set that allows for the 
quantification of the SMF volume in several slices covering the treatment area. In the follow up 
MRI exam, slices will be positioned as s imilar as possible to the first MRI exam.  
Images should be saved in a DICOM format and include the date completed and subject’s 
screening number to be transferred home the Sponsor’s request for central analysis.  
Submental volume analysis will be performed by computer -assisted tools and calculation of 
submental volume will be completed prior to dosing and after treatment.  
8.9 2-D Standardized  Photography   
Standardized  photography  (2-dimensional)  of the face (SMF  area)  will be conducted  at screening 
and on study visits Day 2, Day 4, Day 7, Day 14, Day 21, Day 28, Day 56, and Day 84.  
Photographs  will be taken  with a digital  camera  according  to photography  standards  in 
dermatology surgeries for the face/neck area (see Appendix A). 
8.10 Subject’s Satisfaction Questionnaire  
Subject’s satisfaction questionnaire (yes/no questions) will be conducted by the subjects at 
screening and on study visits Day 28, Day 56 and Day 84.  
Subjects will be asked the following questions and will score their satisfaction based on the grades 
below:  
How  satisfied  are you currently  with the appearance  of your chin,  neck  and jawline  area?  
Score  Grade  
0 Extremely  Satisfied  
1 Satisfied  
2 Somewhat  satisfied  
3 Neither  Satisfied  nor Dissatisfied  
4 Somewhat  Dissatisfied  
5 Dissatisfied  
6 Extremely  Dissatisfied  
How  happy are  you with  the appearance  of your neck  as it relates to  your chin fat? 
Score  Grade  
0 Extremely  Satisfied  
1 Satisfied  
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 34 of 44 CONFIDENTIAL  
 2 Somewhat  satisfied  
3 Neither  Satisfied  nor Dissatisfied  
4 Somewhat  Dissatisfied  
5 Dissatisfied  
6 Extremely  Dissatisfied  
 
How  satisfied  are you with the  result of  your treatment*?  
Score  Grade  
0 Very satisfied  
1 Satisfied  
2 Somewhat satisfied  
3 Somewhat dissatisfied  
4 Dissatisfied  
5 Very dissatisfied  
How  likely  would  you be to  recommend  this procedure  to friends  and family*?  
Score  Grade  
0 Extremely likely  
1 Very likely  
2 Somewhat likely  
3 A little likely  
4 Not at all likely  
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 35 of 44 CONFIDENTIAL  
 8.11 Biochemistry  
Blood samples for the laboratory evaluation of biochemistry parameters will be collected at 
screening and at study visits Day 2, Day 7, 28 and Day 84.  
If there are clinically significant alerts obtained on Day 7, an unscheduled visit will be added for 
additional blood sampling.  
Complete blood cell count (CBC) will include a standard red blood cell (RBC), white blood cell 
(WBC) with differential, hemoglobin, hematocrit, platelets.  A comprehensive metabolic panel will 
include serum alkaline phosphatase  (ALP) , alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), glucose, calcium, globulin ( calculated), phosphorus, chloride, sodium, 
potassium, blood urea nitrogen (BUN) /creatinine  ratio (calculated) , creatinine with GFR 
estimated,  total bilirubin, albumin,  albumin/glo bulin ratio (calculated),  total protein, amylase, 
bicarbonate/carbon dioxide (CO 2), uric acid,  gamma -glutamyl trans ferase (GGT),  and lactate 
dehydrogenase (LDH).  
Biochemistry parameters will be collected for safety assessments.  
8.12 Vital Signs  
Vital signs (systolic and diastolic sitting position blood pressure, pulse rate, respiratory rate, and 
body oral temperature) will be obtained at screening, baseline (pre and post dose) and at study 
visits Day 2, Day 4, Day 7,  Day 14, Day 21,  Day 28 , Day 56  and Day 84 . 
Vital signs will be collected for safety assessments.  
8.13 ECG  
ECG tests will be performed at screening and at study visits Day 7 and Day 84. ECG will be 
performed in triplicates.  
ECGs will be collected for safety assessments.  
8.14 Visual Analog Scale (VAS)  
Pain will be assessed as part of the AEs using  Visual Analog Scale (VAS) . A scale between 0 to 
10 will describe the pain level, where 0 represents no pain and 10 score is intolerable pain. A score 
of 1-3 is categorized as mild, 4 -6 is moderate and 7 -10 is severe. VAS will be assessed on Day 1 
(after injection), Day 2, Day 4, Day 7 , Day 14, Day 21, Day 28, Day 56 and Day 84.  
8.15 Adverse Events and Serious Adverse Events  
8.15.1  Collection of Adverse Events Data  
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with 
the use of an investigational (medicinal) product (IP) or other protocol -imposed intervention, 
regardless of attribution.  An AE may include intercurrent illnesses  or injuries that represent an 
exacerbation (increase in frequency, severity, or specificity) of pre -existing conditions (e.g., 
worsening of asthma).  A laboratory abnormality will be reported on the “Adverse Event” case 
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 36 of 44 CONFIDENTIAL  
 report forms only if it is associated with clinical sequelae or requires therapeutic intervention.  
Whenever possible, it is preferable to record a diagnosis as the AE term rather than a series of 
symptoms relating to a diagnosis.  AEs will be coded accord ing to the Medical Dictionary for 
Regulatory Activities (MedDRA) and graded for severity.  In case the AE severity is changed from 
one severity grade to the another the date of AE start and AE end of the specific AE severity should 
be recorded.  
The reporting period for AEs starts afte r dosing of study drug and will end at final study visit . If 
an AE remains unresolved at discharge, the subject will be followed, at the Investigator’s 
discretion, until resolution of the event or until the subject is deemed “lost to follow -up”.    SAEs 
must be followed until resolution by the PI, even if this ex tends beyond the study -reporting period.  
Resolution is defined as the return to baseline status or stabilization of the condition with the 
expectation that i t will remain chronic.  
The Investigator will assess AEs for severity, relationship to IP, and as to whether the event meets 
one or more of the definitions of an SAE.  The assessments will be recorded on the source 
documents and AE CRF, using the categories defined below.  
Causality 
Category  Description  
Unrelated  A clinical event, including laboratory test abnormality, with a 
temporal relationship to drug administration which  makes a causal 
relationship improbable, and in which other drugs, chemicals or 
underlying disease provide plausible  explanations. For the purpose of 
this protocol, the term unlikely will be considered not related to study 
medication and an “Adverse Event”.  
Related  A clinical event, including laboratory test abnormality, with a 
reasonable time sequence to administration of the  drug, but which 
could also be explained by concurrent disease or other drugs or 
chemicals. Information on drug withdrawal may  be lacking or unclear. 
For the purpose of this protocol, an event that has possible or probable 
relationship to study medication will be defined as a “Suspected 
Adverse Drug Reaction”.   
In order to classify AEs and diseases, preferred terms will be assigned by the sponsor or its 
designee to the original terms entered on the CRF, using MedDRA.  
AEs will be graded for severity according to the following definitions:  
Table 5 Severity Assessment of Adverse Events  
Common Term  Description  
Mild  Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated.  
Moderate  Moderate; minimal, local  or noninvasive intervention indicated; 
limiting age -appropriate instrumental Assisted Daily Living 
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 37 of 44 CONFIDENTIAL  
 Common Term  Description  
(ADL).  
Severe  Severe or medically significant but not immediately life -
threatening; hospitalization or prolongation of hospitalization 
indicated; disabling; limiting self -care ADL.  
Life-Threatening  Life-threatening consequences; urgent intervention indicated.  
Death  Death related to AE  
8.15.2  Serious Adverse Events  
According to the ICH Guidelines for Good Clinical Practice (E6), an SAE is any untoward 
medical occurrence during the course of a clinical investigation that is characterized by one or 
more of the following:  
• Results in death  
• Is life -threatening  
• Requires in -subject hospitalization or prolongation of existing hospitalization  
• Results in persistent or significant disability/incapacity  
• Is a congenital anomaly/birth defect  
• Important medical events  
Although not an SAE, exposure to study drug during pregnancy, even if no AE is reported in the 
mother, should be reported within 24 hours.  
8.15.3  Reporting Requirements for Serious Adverse Events  
All SAEs must be reported to the Sponsor  by the Investigator, study coordinator, other designated 
study personnel, or clinical research associate within 24 hours of notification of the SAE. To report 
such events, an SAE form must be completed by the Investigator and sent within 24 hours by email  
or fax with relevant information.  
Within the 48 hours following the initial report, the Investigator must provide further information 
on the SAE if available. This should include a copy of the completed SAE form, and any other 
information that will assist the understanding of the event. Si gnificant new information on ongoing 
SAEs should be provided promptly as a follow -up. 
The Investigator also must report all SAEs promptly to the appropriate IRB/EC as required by 
the institution within 24 hours or 48 hours if on weekend/holiday.  
Report SAEs by:  
 
 
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 38 of 44 CONFIDENTIAL  
 Report SAEs by  
SAE Hotline: 888 -746-7231  
SAE Fax Line: 888 -746-3293  
SAE Email: rho_productsafety@rhoworld.com  
 
Table 6 Contact Information for SAE Reporting  
Primary Contact  Sponsor Contact  
Lead Product Safety Specialist  Medical Monitor:  
Bonnie Graham, RN, BSN  Patricia Walker, MD  
Mobile:  Mobile:  Mobile:  1-805-705-5853  
Email:  Email:  Email:  dr.patricia.walker@gmail.com  
8.15.4  Reporting pregnancy  
Pregnancy testing must be p erformed on all women of childbearing potential prior to dosing , and 
all the results of all pregnancy tests are to be recorded in the eCRF’s. All women must have a 
negative pregnancy test to be enrolled into the study. If a pregnancy test turns positive after study 
drug treatment, the patient will be discontinued and protocol -required procedures for study 
discontinuation and follow -up mus t be pe rformed. The subject will be followed to determine the 
outcome of the pregnancy.  All women of childbearing potential should be instructed to contact 
the investigator if they su spect they might be pregnant (e.g. missed or late menstrual period) at any 
time during the study.  
The investigator must notify the sponsor  of any pregnancies in accordance with the SAE reporting 
procedures described in section 8.14.3.  Note, while the pregnancy is not considered an AE or an 
SAE, any pregnancy complication or newborn complication will be reported as an AE or SAE if 
it meets the criteria.   Follow -up information regarding the course of pregnancy, including perinatal 
and neonatal outcomes and, where applicable, offspring information must be reported on the 
Pregnancy Outcome eCRF.    
8.15.5  Recording of Serious Adverse Events  
All SAE information must be recorded on the SAE form provided by the Sponsor. Additional 
follow -up information (e.g., test results, autopsy, and discharge summary) must be obtained to 
supplement the SAE report form. A copy of all initial and follow -up repo rts must be filed with the 
subject’s eCRF.  
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 39 of 44 CONFIDENTIAL  
 9.0 STATISTICAL CONSIDERATIONS  
9.1 Sample Size Determination  
A total of 75 subjects will be included in the study . All subject s will be treated with RZL -012. 
Each 15 subjects will be randomized into each of the treatment groups.  
9.2 Analysis Data Sets  
Subjects who receive study treatment  will be included in the safety analyses.  
9.3 Endpoints  Analyses  
All measured variables and derived parameters will be listed individually and, if appropriate, 
tabulated by descriptive statistics.  
For categorical variables, summary tables will be provided giving sample size, absolute and 
relative frequency, and 95% confidence interval (CI) for proportions by study arm.  
For continuous variables, summary tables will be provided giving sample size, arithmetic mean, 
standard deviation, coefficient of variations (CV%), median, minimum and maximum, and 95% 
CI for means of variables by study arm.  
Primary endpoint and exploratory endpoints  will be analyzed in descriptive manner.  
The data will be analyzed using the SAS version 9.4 (SAS Institute, Cary North Carolina).  
9.4 Safety  
Safety data will be summarized by dose group and based on their initial dose level or treatment 
group (i.e., if a dose reduction occurs,  they will be considered in their initial group). Descriptive 
statistics will be provided for actual values and change from baseline values for vital signs , blood 
parameters, ECG . 
AE assessment and treatment area evaluation including, but not limited to evaluation of edema, 
pain, bruising, erythema, induration, numbness, paresthesia, tenderness, and pruritus . Pain in the 
injection site  will be assessed by Visual Analog Scale (VAS) in each of the visits.  Injection site 
pain will not be recorded as an AE.  
The incidence and severity of AEs reported during the study and their relationship to study drug 
will be tabulated. AEs will be coded using MedDRA™ and will be presented by body system.  
AEs related to nerve damage such as: paralysis, mandibular neuropathy, facial palsy will be AEs 
with special interest, i.e., the PI will write a detailed narrative on these specific AEs.  
AE data will be listed individually and summarized by SOC and by PT within a system organ 
class.  
Skin irritancy AEs related to the injection procedure will be evaluated for frequency, severity and 
duration by treatment group.  
Laboratory tests and ECG results will be summarized in appropriate table.  
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 40 of 44 CONFIDENTIAL  
 10.0 DATA  COLLECTION, STUDY MONITORING, AND DATA DISCLOSURE  
10.1 Data Collection and Reporting  
An eCRF will be completed for each subject who receives at least one dose of study drug. All 
entries on the eCRF must be supported by original source documentation (e.g.,  laboratory reports, 
medical records) maintained at the investigational site.  
The Investigator will make all safety assessments (AEs and vital signs) on an ongoing basis. The 
Investigator is required to review all entries on the eCRF and sign at appropriate time intervals.  
10.2 Study Monitoring  
All aspects of the study will be monitored carefully by the Sponsor’s designees with respect to 
current Good Clinical Practice (GCP) and Standard Operating Procedures (SOP) for compliance 
with applicable government regulations. It is the responsibility of the Investigator to provide all 
study records, including eCRFs, source documents, etc., for review and source document 
verification by the clinical monitor.  
All eCRFs will be 100% source verified against corresponding source documentation (e.g., office 
and clinical laboratory records) for each subject. Clinical monitors will evaluate periodically the 
progress of the study, including the verification of appropriate consent form procedures, review of 
drug accountability and preparation procedures, adherence to dosing procedures, and the 
verification of the accuracy and completeness of eCRFs. Clinical monitors will also ensure that all 
protocol requirements, appli cable FDA regulations, other requirements, and Investigator’s 
obligations are being fulfilled.  
10.3 Audit and Inspection  
The sponsor or representative may conduct audits at the trial site(s). Audits will include, but are 
not limited to protocol compliance, drug supply, presence of required documents, the informed 
consent process, and comparison of eCRFs with source documents . The investigator agrees to 
participate with audits conducted at a reasonable time in a reasonable manner.  
Regulatory authorities worldwide may inspect the trial site during or after the trial. The investigator 
should contact the sponsor immediately if this occurs and must fully cooperate with the inspections 
conducted at a reasonable time in a reasonable manne r.  
10.4 Deviation from Clinical Trial Protocol  
Deviations from the protocol are to be avoided. If a deviation occurs, the Investigator must 
promptly report the deviation to the study monitor.  
The Investigator (or designee) will record any failure to follow the protocol because of any other 
medical unavoidable reason to avoid the subject's urgent risk and record a document as soon as 
possible stating this and the reason. It must be submitted to the sponsor and the director of the 
study site.  
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 41 of 44 CONFIDENTIAL  
 10.5 Retention of Records  
The Investigator  must retain all study records required by Raziel and by the applicable regulations 
in a secure and safe facility. The Investigator  must notify Raziel  of any change in the location, 
disposition or custody of the study files. The Investigator  /institution must take measures to prevent 
accidental or premature destruction of essential documents, that is, documents that permit 
evaluation of the conduct of a study and the quality of the data produced, including paper copies 
of study records (e.g. , subject charts) as well as any original source documents that are electronic 
as required by applicable regulatory requirements . 
All study records must be retained until whichever is the later day in the following : (1) At least the 
date of approval for the drug or (2) the date when 3 years have passed since the discontinuation or 
completion of the study . No records relating to this study should be disposed of without the written 
approval of Raziel . It is the responsibility of Raziel  to inform the Investigator /institution as to when 
these documents no longer need to be retained . 
10.6 Data Disclosure and Subject Confidentiality  
Subject medical information  and video recordings  obtained as a result of this study is considered 
confidential  and used only for study evaluation purposes . Disclosure to third parties other than 
those noted below is prohibited. All reports and communications relating to subjects in this study 
will identify each subject only by number. Medical information resulting from a subject’s 
participation in this stud y may be given to the subject’s personal physician or to the appropriate 
medical personnel responsible  for the subject’s welfare. Data generated as a result of this study are 
to be available for inspection on request by FDA or other government regulatory agency auditors, 
the Sponsor clinical monitor (or designee), and the IRB/EC.  
All laboratory specimens, evaluation forms, reports, and other records that leave the site will be 
identified by a coded number to maintain subject confidentiality. All records will be kept in a 
locked and secured area. All computer entry and networking pr ograms will be identifiable only by 
coded numbers. Clinical information will not be released without written permission from the 
subject, except as necessary for monitoring by the IRB, the FDA, or other government authorities 
where the clinical data will b e used for new drug registration,  or the study Sponsor.  
Any information, inventions, or discoveries (whether patentable or not), innovations, suggestions, 
ideas, and reports, made or developed by the Investigator(s) as a result of conducting this study 
shall be promptly disclosed to the Sponsor and shall be the  sole property of the Sponsor. The 
Investigator agrees, upon the Sponsor’s request and at the Sponsor's expense, to execute such 
documents and to take such other actions, as the Sponsor deems necessary or appropriate, to obtain 
patents in the Sponsor’s nam e covering any of the foregoing.  
The results of this study will be published under the direction of the Sponsor. Results will not be 
published without prior review and approval by the Sponsor and Study Investigator.  
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 42 of 44 CONFIDENTIAL  
 11.0 PROTECTION OF HUMAN SUBJECTS  
11.1 Basic Principles  
The study will be conducted in accordance with the relevant regulatory requirements, this protocol, 
and ethical principles that are consisted with the GCP guideline developed by the International 
Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for 
Human Use (ICH ). This clinical trial will also be conducted in compliance with Declaration of 
Helsinki, protocol, Standard specified in the relevant local regulations . Prior to initiation of the 
study, the investigator and  the sponsor should obtain approval from the IRB/IEC on this protocol 
and any further amendments, and the subject information and informed consent form . 
Any suspected serious breaches must be immediately reported to the sponsor. A serious breach is 
a breach of the conditions and principles of GCP in connection with the study or the protocol, 
which is likely to affect, to a significant degree, the safety of  the subjects or the scientific value of 
the study.  
Personnel involved in the study will be qualified by education, training, and experience to 
perform their respective tasks.  
11.2 Institutional Review Board/Ethics Committee  
The Investigator or designee agrees to provide the IRB/EC with all appropriate material, including 
a copy of the ICF. The study will not be initiated until the Investigator obtains written approval of 
the research plan and the ICF from the appropriate IRB/EC and copies of these documents are 
received by the Sponsor. Appropriate reports on the progress of this study will be made by the 
Investig ator to the IRB/EC and Sponsor in accordance with applicable government regulations and 
in agreement with the policies established by the Sponsor. The Sponsor ensures that the IRB/EC 
complies with the requirements set forth in 21  CFR Part 56  (Code of Feder al Regulations) . 
11.3 Informed Consent  
Prior to initiation of any study procedures, each subject will undergo an Informed Consent process 
in which the subject voluntarily confirms their willingness to participate in the trial. The 
Investigator or his/her approved designee must explain the natur e of the study protocol and 
associated risks to the potential study participant. The potential participant must be allowed to 
review the study information and to ask questions before being asked to sign the Informed Consent 
Form (ICF). Written informed con sent must be provided by the potential study participant prior to 
initiation of any screening evaluations or other study -related procedures. The signature date and 
the name of the individual at the site who obtained the informed consent will be recorded in  the 
subject’s medical record.  
The ICF approved by the IRB/EC will contain a description of the study’s purpose, purpose, 
procedures, inconveniences and potential risks, and anticipated benefits. Prior to participation in 
the trial, the subject will receive a copy of the signed and date d written ICF. During participation 
in the trial, the subject will receive a copy of the signed and dated consent form updates and a copy 
of any amendments to the ICF provided to the subjects.  
Raziel Therapeutics, Ltd.  Protocol RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1 .2 
15 November  2022  Page 43 of 44 CONFIDENTIAL  
 After written informed consent is obtained, the subject will be assigned a screening number and 
will undergo the designated screening procedures listed in Section 1.2 . The Investigator, sub -
investigator or delegate will assess the results of these screening evaluations to determine 
eligibility for entry into the study according to the inclusion/exclusion criteria listed in Section 5.0. 
11.4 Subject Health Injury and Insurance  
In general, if a subject is health -injured as a direct result of the investigational products, the sponsor 
or its contracted insurance company will pay for reasonable and necessary medical treatment for 
the health -injury. If laws or regulations of the locality in which the study i s taking place require 
additional payment of expenses, the sponsor should comply with such laws or regulations. Where 
applicable, the sponsor will arrange for specific insurance coverage. If health damage occurred in 
subject partic ipating the clinical trial due to the willful or gross negligence of investigator’s site, 
indemnification will be discussed based on the contract with the site. The indemnification for the 
health damage and the payment to subjects will be described in the ICF. 
11.5 Completion of the Study  
If the clinical trial is completed at the study site, the investigator will notify the director of the 
study site that the trial has been completed and provide an approximate summary in writing.  The 
director of the study site will promptly notify the IRB/EC and the Sponsor in writing about the 
completion.  
 
Raziel Therapeutics, Ltd.  Protocol RZL -012- RZL -012-SMF -SWMTG -P2US -001 
RZL -012 Version: 1. 2 
 
15 November  2022                                              44 of 44                                                CONFIDENTIAL                                                                                                         
Appendix A:  Photographic Standards of the Face Area   
 
 
 
 
 
 
 
